Systemic sclerosis & Raynaud's
Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis
Authors' conclusion
Relma-cel therapy in patients with SSc led to early clinical improvement, supported by CAR-T cell expansion, B cell depletion, and a favorable safety profile. Proteomic alterations were associated with the observed clinical improvements and suggested broad remodeling of inflammatory and fibrotic pathways.
Study context
- Population
- Patients with progressive systemic sclerosis (SSc)
Methodological detailsSomaScan plasma proteomics
- SomaScan plasma proteomics
Main finding
As reported in the abstract
- Sustained clinical improvement across multiple SSc domains, incl. skin involvement and patient- and physician-assessed disease activity
- Rapid B cell depletion followed by immune reconstitution
- Coordinated longitudinal changes in proteins and pathways of inflammation, fibrosis, vascular remodeling and immune regulation
- Day 180: down-regulation of profibrotic/inflammatory proteins and up-regulation of proteins potentially linked to vascular repair or immune regulation
- Pathway analyses: broad attenuation of inflammatory and fibrotic programs with relative enhancement of repair-associated processes
Observational data: associations, not effects.
Safety
- Manageable safety profiles
Original publication
Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis. Arthritis Rheumatol. Published 1 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →